4//SEC Filing
Session R.A. II 4
Accession 0001209191-21-004573
CIK 0001806310other
Filed
Jan 19, 7:00 PM ET
Accepted
Jan 20, 8:22 PM ET
Size
5.5 KB
Accession
0001209191-21-004573
Insider Transaction Report
Form 4
Session R.A. II
DirectorPresident and CEO10% Owner
Transactions
- Award
Stock Option (Right to Buy)
2021-01-19+199,700→ 199,700 totalExercise: $31.00Exp: 2031-01-19→ Common Stock (199,700 underlying)
Footnotes (1)
- [F1]25% of the total number of shares underlying the option shall vest and become exercisable on January 19, 2022 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Documents
Issuer
Taysha Gene Therapies, Inc.
CIK 0001806310
Entity typeother
Related Parties
1- filerCIK 0001701846
Filing Metadata
- Form type
- 4
- Filed
- Jan 19, 7:00 PM ET
- Accepted
- Jan 20, 8:22 PM ET
- Size
- 5.5 KB